Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug ...

This week brought new partnerships, mergers and CEOs to Greater Boston’s biotech scene. Check out the latest news involving C4 Therapeutics, Merck KGaA, Akari Therapeutics and more. Major ...

Merck & Co. Inc. will spend up to $610 million ... Public records offer clues. Boston gene therapy company's shares rise after going public via SPAC Boston gene therapy company's shares rise ...

WASHINGTON (AP) — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ...

Big Pharma is all about beefing up its presence in the Boston area--a hotspot for biotech. And Merck KGaA is the latest to undertake a construction project. Tuesday, the German drugmaker announced ...

Leading CIOs honored for leadership, innovation, and business impact BOSTON, June 06, 2025 (GLOBE NEWSWIRE) -- The 2025 ...

The Cambridge lab, originally a Schering-Plough facility, will be phased out over two years and a few jobs will be moved to Merck’s Boston site in the Longwood Medical Area. The $41 billion ...

That spokesperson assured me, however, that "a majority of the people and the labs in Seattle will be moved to our state-of-the-art basic research facility in Boston." So Schadt's position at Merck is ...

Drug giant Merck is buying Lexington-based Cubist Pharmaceuticals Inc. in a whopping $9.5 billion deal a top state official said will spur growth in the Bay State’s life sciences sector.

Frazier, who is retiring as chairman of Merck on Dec. 1, joined STAT to both reflect and to look toward the future at the annual STAT Summit in Boston earlier this month. He talked about the role ...

Frazier, chief executive of Merck, based in Whitehouse Station, N.J. Frazier hosted the company’s first investor presentation at its 10-year-old Boston research lab in the Longwood Medical Area.